Hcmed (6934.TWO) operates in the Biotechnology industry within the Healthcare sector. Full company description, peers, and segment breakdown are on the page above.

What is 6934.TWO's market cap?

Hcmed (6934.TWO) has a market capitalization of approximately $5.58 billion, as of January 30, 2026, based on the most recent share price and shares outstanding.

Does 6934.TWO pay a dividend?

No — Hcmed (6934.TWO) does not currently pay a regular dividend. Many growth-stage companies reinvest earnings into the business instead of returning capital to shareholders. The Dividend tab tracks any future declarations.

Is 6934.TWO profitable?

Hcmed (6934.TWO) currently reports negative earnings on a trailing-twelve-month basis. The Earnings and Financials tabs show the full EPS history, revenue trend, and analyst forecasts for future profitability.

6934.TWO (Hcmed) is no longer actively trading.

This usually means the company was acquired and taken private, delisted from its exchange, or its ticker has been retired. Every price, valuation, dividend, and analyst figure on this page is frozen at the last available trading session and reads as historical reference — not a current-day signal.

6934.TWO

Hcmed

TWO·Biotechnology · Healthcare

NT$155.00NT$0.00+0.00%

Market capNT$5.58B·Jan 30 6:59 AM UTC

Frequently Asked Questions About 6934.TWO

What does Hcmed do?: Hcmed (6934.TWO) operates in the Biotechnology industry within the Healthcare sector. Full company description, peers, and segment breakdown are on the page above.
What is 6934.TWO's market cap?: Hcmed (6934.TWO) has a market capitalization of approximately $5.58 billion, as of January 30, 2026, based on the most recent share price and shares outstanding.
Does 6934.TWO pay a dividend?: No — Hcmed (6934.TWO) does not currently pay a regular dividend. Many growth-stage companies reinvest earnings into the business instead of returning capital to shareholders. The Dividend tab tracks any future declarations.
Is 6934.TWO profitable?: Hcmed (6934.TWO) currently reports negative earnings on a trailing-twelve-month basis. The Earnings and Financials tabs show the full EPS history, revenue trend, and analyst forecasts for future profitability.

6934.TWO (Hcmed) is no longer actively trading.

6934.TWO

Hcmed

TWO·Biotechnology · Healthcare

NT$155.00NT$0.00+0.00%

Market capNT$5.58B·Jan 30 6:59 AM UTC

Price Chart

NT$155.00+NT$0.00 (+0.00%)today

+121.75%CAGR +44.38%

Select date range

FromTo

Jun 25, 2024Jun 25, 2024 → Aug 26, 2026· 2.2 yrsAug 26, 2026

Key Metrics

6934.TWO does not currently pay a dividend.

EarningsEarnings Tab

EPS (FWD)—

P/E Ratio (FWD)—

EPS Growth (1Y)—

EPS Growth (3Y)—

EPS Growth (5Y)—

Next Earnings Date—

Last Report Date—

Reported vs Estimate—

Earnings Surprise—

FinancialsFinancials Tab

RevenueNT$145.94M

Net Income−NT$143.20M

Net Margin−98.1%

Operating Cash Flow−NT$74.99M

Capital ExpendituresNT$69.44M

Free Cash Flow−NT$144.44M

Return on Equity−53.7%

Return on Invested Capital−11.5%

Net CashNT$172.21M

Value Graph

PRO

See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.

Click below to see what's inside, then upgrade to unlock for 6934.TWO and 80,000+ other tickers.

EPS · Price vs. Fair Value Price Fair

Income Statement Flow

PRO

See exactly how 6934.TWO's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.

The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for 6934.TWO and 80,000+ other tickers.

About Hcmed

HCmed Innovations Co Ltd. specializes in creating advanced solutions for respiratory treatment through the application of mesh technology. Their product line features devices such as Pulmogine and AdheResp. Beyond its core offerings, the company delivers extensive analytical services focused on aerosol characterization, helping clients optimize and develop new inhaled therapeutic products. This analytical assistance is provided in strict adherence to Pharmacopoeia standards. Founded on October 6, 2014, by Jason Cheng, Leon Tsai, Shaogi Huang, and Simon Hsieh, HCmed maintains its principal office in Taipei, Taiwan.

CEO: Jason Cheng
Sector: Healthcare
Industry: Biotechnology
Exchange: TWO
Employees: 61
Website: www.hcmed-inno.com

Peers

Peers Tab

4168.TWO

GlycoNex Incorporation

Advagene Biopharma Co., Ltd.

Cap

NT$1.8B

Latest News

News Tab

No recent news available.

Frequently Asked Questions About 6934.TWO

What does Hcmed do?: Hcmed (6934.TWO) operates in the Biotechnology industry within the Healthcare sector. Full company description, peers, and segment breakdown are on the page above.
What is 6934.TWO's market cap?: Hcmed (6934.TWO) has a market capitalization of approximately $5.58 billion, as of January 30, 2026, based on the most recent share price and shares outstanding.
Does 6934.TWO pay a dividend?: No — Hcmed (6934.TWO) does not currently pay a regular dividend. Many growth-stage companies reinvest earnings into the business instead of returning capital to shareholders. The Dividend tab tracks any future declarations.
Is 6934.TWO profitable?: Hcmed (6934.TWO) currently reports negative earnings on a trailing-twelve-month basis. The Earnings and Financials tabs show the full EPS history, revenue trend, and analyst forecasts for future profitability.